Gestational diabetes mellitus (GDM) is defined as impaired glucose tolerance with onset or first recognition during pregnancy, which is characterized by an increased insulin resistance. Gestational ...diabetes mellitus is associated with pregnancy-related maternal and fetal morbidity (both antenatal and perinatal). Myo-inositol has been suggested to improve insulin resistance in women with polycystic ovary syndrome. The aim of this study is to examine the impact of myo-inositol supplementation during pregnancy on the incidence of gestational diabetes mellitus.
We will conduct a single-center, open-label, randomized controlled trial. A total of 160 healthy pregnant women with singleton pregnancy at 11-13
weeks of gestation will be randomly allocated in two groups: intervention group (N = 80) and control group (N = 80). The intervention group will receive myo-inositol and folic acid (4000 mg myo-inositol and 400 mcg folic acid daily) from 11 to 13
weeks of gestation until 26-28 weeks of gestation, while the control group will receive folic acid alone (400 mcg folic acid daily) for the same period of time as intervention group. The primary outcome will be gestational diabetes incidence rate at 26-28 weeks of gestation, according to the results of a 75 g oral glucose tolerance test held at 26-28 weeks of gestation. The secondary outcomes will include fasting blood glucose levels, glycated hemoglobin levels, insulin resistance level (evaluated by homeostasis model assessment of insulin resistance and Matsuda Index), and incidence rate of diet-treated gestational diabetes and diabetes requiring insulin therapy at 26-28 weeks of gestation.
This trial will provide evidence for the effectiveness of myo-inositol supplementation during pregnancy in reducing the incidence of gestational diabetes mellitus.
ISRCTN registry: ISRCTN16142533 . Registered on 9 March 2017.
Diabetes Mellitus and Colorectal Cancer Risk Kallergi, Aggela; Chambre, Claire; Duchemann, Boris ...
Current colorectal cancer reports,
08/2015, Letnik:
11, Številka:
4
Journal Article
Recenzirano
Colorectal cancer is the third most common cancer, after lung/bronchus, breast, or prostate cancer. The association between diabetes and cancer has been reported in many cohorts, with an association ...described in both colon cancer and rectal cancer, in both genders. Duration could be a determinant factor of the risk. The relationship between diabetes and colorectal cancer could be directly due to hyperglycemia or indirectly via hyperinsulinemia or elevated levels of IGF-1, even more as both diseases share common risk factors such as obesity. Antidiabetic treatments should be taken in account; treatment by metformin could decrease colorectal cancer risk whereas sulfonylureas or insulin seem to be associated with an increased risk. However, epidemiological studies include different biases. Indeed, implication of insulin therapy itself is uncertain. Some authors suggest that colorectal cancer screening should be proposed earlier in all patients with type 2 diabetes without current recommendations.
PDF
